Surface Oncology, Inc. (SURF) Social Stream



Surface Oncology, Inc. (SURF): $1.77

-0.12 (-6.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Surface Oncology Inc (SURF) Price Targets From Analysts

Use the tables below to see what analysts covering Surface Oncology Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-08 5 $17 $14 $15 $3.11 382.32%
2022-03-03 4 $17 $10 $13.666 $3.11 339.42%

The Trend in the Analyst Price Target


SURF's average price target has moved down $2.65 over the prior 34 weeks.

SURF reports an average of 169.28% for its upside potential over the past 47 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-04 5 18 14 16.4 8.17 100.73%
2021-08-07 5 18 14 15.6 5.70 173.68%
2021-08-19 5 18 14 15.6 5.38 189.96%
2021-09-11 5 18 14 15.6 6.11 155.32%
2021-09-19 5 18 14 15.6 7.10 119.72%

SURF Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 4 0 0 0 0 4

The Trend in the Broker Recommendations


Over the past 43 weeks, SURF's average broker recommendation rating improved by 0.6.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • To contextualize these metrics, consider that out of all US stocks, Surface Oncology Inc's upside potential (average analyst target price relative to current price) is greater than 471.22% of them.
  • Surface Oncology Inc's average analyst price target is higher than 74.31% of all US stocks.
  • Surface Oncology Inc's number of analysts covering the stock is greater than 155.93% of Healthcare stocks.
  • In terms of how Surface Oncology Inc fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -59.8% of that group.

In the Pharmaceutical Products industry, STRO, SRZN, and SRRK are the three stocks most similar to Surface Oncology Inc regarding the price target and analyst recommendation information presented here.

Is SURF a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.649 seconds.